Michael Porter has over 17 years of experience leading product development, regulatory submissions, and product launches within the infectious disease, companion diagnostics/oncology, and defense industries. He has led programs to developing a wide range of technologies, including fully automated PCR assays, next-generation sequencing, flow cytometry and cellular pathology diagnostics. Prior to joining ASELL Mr. Porter held technical and leadership roles in research and development at Becton Dickinson where he drove the advancement of fully automated nucleic acid detection assays including multiple FDA 510(k) submissions and CE-mark filings. As a Senior Portfolio Program Manager at GuardantHealth, Mr. Porter developed and managed the international product portfolio including world-wide regulatory submissions/filings and technology transfer programs with partners in the EU and China. Mr. Porter holds dual B.S. degrees from the University of Maryland in Biochemistry and Mathematics as well as a M.S. in Biotechnology from The Johns Hopkins University.